ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000433

Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation

Identifieur interne : 000433 ( PascalFrancis/Curation ); précédent : 000432; suivant : 000434

Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation

Auteurs : Brad Hagen [Canada] ; Chris Armstrong Esther [Canada] ; Roland Ikuto [Canada] ; Robert J. Williams [Canada] ; Carole-Lynne Le Navenec [Canada] ; Morgan Aho

Source :

International psychogeriatrics [ 1041-6102 ] ; 2005.

RBID : Pascal:05-0418553

Descripteurs français

Pascal (Inist)
- Neuroleptique, Chimiothérapie, Traitement, Psychotrope, Canada, Long terme, Epidémiologie, Prévalence, Santé publique, Démence sénile, Etablissement troisième âge, Article synthèse, Parkinson maladie, Personne âgée.
Wicri :
- geographic : Canada.
- topic : Santé publique, Personne âgée.

English descriptors

KwdEn :
- Canada, Chemotherapy, Elderly, Epidemiology, Homes for the aged, Long term, Neuroleptic, Parkinson disease, Prevalence, Psychotropic, Public health, Review, Senile dementia, Treatment.

Abstract

Background and aims: Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation. Method: A comparative descriptive design was used. Pharmacy and chart data on antipsychotic use were gathered for three separate one-month periods during one year. Data were collected both in a facility experiencing relocation of all residents to a new facility, and in a facility not undergoing relocation. The three one-month data collection periods covered a one-month period before the relocation, immediately after the relocation, and six months after the relocation. Results: In the facility not experiencing relocation, an average of 31.3% of all residents were receiving antipsychotics. Residents in this facility received antipsychotics for an average length of 0.81 years, and 20.8% of all antipsychotic prescriptions reflected dose reductions within six months of the start of the prescription. Only 8.1% of prescriptions had accompanying documentation on the behavioral indication for the use of antipsychotics. A total of 73.4% of all antipsychotics were 'atypical' antipsychotics, and 13.5% of all antipsychotic prescriptions were written as 'p.r.n.' (as needed). While the use of antipsychotics remained relatively constant in the non-relocation facility (between 30.3% and 33.1% of all residents), the percentage of residents receiving antipsychotics in the facility experiencing a relocation climbed significantly; from 21.5% six months before the move, to 32.6% immediately after the move, to 36.9% six months after the move. Conclusion: These findings, when compared with the U.S. standards on antipsychotic use (OBRA), suggest the need for additional research on antipsychotic use in Canadian LTC facilities.

A01	`01`	`1`		`@0 1041-6102`
A03		`1`		`@0 Int. psychogeriatr.`
A05				`@2 17`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation`
A11	`01`	`1`		`@1 HAGEN (Brad)`
A11	`02`	`1`		`@1 ESTHER (Chris Armstrong)`
A11	`03`	`1`		`@1 IKUTO (Roland)`
A11	`04`	`1`		`@1 WILLIAMS (Robert J.)`
A11	`05`	`1`		`@1 LE NAVENEC (Carole-Lynne)`
A11	`06`	`1`		`@1 AHO (Morgan)`
A14	`01`			`@1 School of Health Sciences, The University of Lethbridge @2 Alberta @3 CAN @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Senior's Health, The Chinook Health Region @2 Lethbridge, Alberta @3 CAN @Z 3 aut.`
A14	`03`			`@1 School of Nursing, The University of Calgary @2 Alberta @3 CAN @Z 5 aut.`
A20				`@1 179-193`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26959 @5 354000131507690030`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.3/4`
A47	`01`	`1`		`@0 05-0418553`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 International psychogeriatrics`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background and aims: Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation. Method: A comparative descriptive design was used. Pharmacy and chart data on antipsychotic use were gathered for three separate one-month periods during one year. Data were collected both in a facility experiencing relocation of all residents to a new facility, and in a facility not undergoing relocation. The three one-month data collection periods covered a one-month period before the relocation, immediately after the relocation, and six months after the relocation. Results: In the facility not experiencing relocation, an average of 31.3% of all residents were receiving antipsychotics. Residents in this facility received antipsychotics for an average length of 0.81 years, and 20.8% of all antipsychotic prescriptions reflected dose reductions within six months of the start of the prescription. Only 8.1% of prescriptions had accompanying documentation on the behavioral indication for the use of antipsychotics. A total of 73.4% of all antipsychotics were 'atypical' antipsychotics, and 13.5% of all antipsychotic prescriptions were written as 'p.r.n.' (as needed). While the use of antipsychotics remained relatively constant in the non-relocation facility (between 30.3% and 33.1% of all residents), the percentage of residents receiving antipsychotics in the facility experiencing a relocation climbed significantly; from 21.5% six months before the move, to 32.6% immediately after the move, to 36.9% six months after the move. Conclusion: These findings, when compared with the U.S. standards on antipsychotic use (OBRA), suggest the need for additional research on antipsychotic use in Canadian LTC facilities.
C02	`01`	`X`		`@0 002B02B03`
C02	`02`	`X`		`@0 002B18C05A`
C02	`03`	`X`		`@0 002B17G`
C02	`04`	`X`		`@0 002B18C13`
C03	`01`	`X`	`FRE`	`@0 Neuroleptique @5 01`
C03	`01`	`X`	`ENG`	`@0 Neuroleptic @5 01`
C03	`01`	`X`	`SPA`	`@0 Neuroléptico @5 01`
C03	`02`	`X`	`FRE`	`@0 Chimiothérapie @5 02`
C03	`02`	`X`	`ENG`	`@0 Chemotherapy @5 02`
C03	`02`	`X`	`SPA`	`@0 Quimioterapia @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 03`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 03`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 03`
C03	`04`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 04`
C03	`04`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 04`
C03	`04`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 04`
C03	`05`	`X`	`FRE`	`@0 Canada @2 NG @5 05`
C03	`05`	`X`	`ENG`	`@0 Canada @2 NG @5 05`
C03	`05`	`X`	`SPA`	`@0 Canadá @2 NG @5 05`
C03	`06`	`X`	`FRE`	`@0 Long terme @5 06`
C03	`06`	`X`	`ENG`	`@0 Long term @5 06`
C03	`06`	`X`	`SPA`	`@0 Largo plazo @5 06`
C03	`07`	`X`	`FRE`	`@0 Epidémiologie @5 07`
C03	`07`	`X`	`ENG`	`@0 Epidemiology @5 07`
C03	`07`	`X`	`SPA`	`@0 Epidemiología @5 07`
C03	`08`	`X`	`FRE`	`@0 Prévalence @5 08`
C03	`08`	`X`	`ENG`	`@0 Prevalence @5 08`
C03	`08`	`X`	`SPA`	`@0 Prevalencia @5 08`
C03	`09`	`X`	`FRE`	`@0 Santé publique @5 09`
C03	`09`	`X`	`ENG`	`@0 Public health @5 09`
C03	`09`	`X`	`SPA`	`@0 Salud pública @5 09`
C03	`10`	`X`	`FRE`	`@0 Démence sénile @5 10`
C03	`10`	`X`	`ENG`	`@0 Senile dementia @5 10`
C03	`10`	`X`	`SPA`	`@0 Demencia senil @5 10`
C03	`11`	`X`	`FRE`	`@0 Etablissement troisième âge @5 12`
C03	`11`	`X`	`ENG`	`@0 Homes for the aged @5 12`
C03	`11`	`X`	`SPA`	`@0 Establecimiento tercera edad @5 12`
C03	`12`	`X`	`FRE`	`@0 Article synthèse @5 13`
C03	`12`	`X`	`ENG`	`@0 Review @5 13`
C03	`12`	`X`	`SPA`	`@0 Artículo síntesis @5 13`
C03	`13`	`X`	`FRE`	`@0 Parkinson maladie @5 14`
C03	`13`	`X`	`ENG`	`@0 Parkinson disease @5 14`
C03	`13`	`X`	`SPA`	`@0 Parkinson enfermedad @5 14`
C03	`14`	`X`	`FRE`	`@0 Personne âgée @5 18`
C03	`14`	`X`	`ENG`	`@0 Elderly @5 18`
C03	`14`	`X`	`SPA`	`@0 Anciano @5 18`
C07	`01`	`X`	`FRE`	`@0 Amérique du Nord @2 NG`
C07	`01`	`X`	`ENG`	`@0 North America @2 NG`
C07	`01`	`X`	`SPA`	`@0 America del norte @2 NG`
C07	`02`	`X`	`FRE`	`@0 Amérique @2 NG`
C07	`02`	`X`	`ENG`	`@0 America @2 NG`
C07	`02`	`X`	`SPA`	`@0 America @2 NG`
C07	`03`	`X`	`FRE`	`@0 Homme`
C07	`03`	`X`	`ENG`	`@0 Human`
C07	`03`	`X`	`SPA`	`@0 Hombre`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 39`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
C07	`07`	`X`	`FRE`	`@0 Système nerveux pathologie @5 40`
C07	`07`	`X`	`ENG`	`@0 Nervous system diseases @5 40`
C07	`07`	`X`	`SPA`	`@0 Sistema nervioso patología @5 40`
C07	`08`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 41`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
N21				`@1 290`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000890

Links to Exploration step

Pascal:05-0418553

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation</title>
<author><name sortKey="Hagen, Brad" sort="Hagen, Brad" uniqKey="Hagen B" first="Brad" last="Hagen">Brad Hagen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Esther, Chris Armstrong" sort="Esther, Chris Armstrong" uniqKey="Esther C" first="Chris Armstrong" last="Esther">Chris Armstrong Esther</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Ikuto, Roland" sort="Ikuto, Roland" uniqKey="Ikuto R" first="Roland" last="Ikuto">Roland Ikuto</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Senior's Health, The Chinook Health Region</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Williams, Robert J" sort="Williams, Robert J" uniqKey="Williams R" first="Robert J." last="Williams">Robert J. Williams</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Le Navenec, Carole Lynne" sort="Le Navenec, Carole Lynne" uniqKey="Le Navenec C" first="Carole-Lynne" last="Le Navenec">Carole-Lynne Le Navenec</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Nursing, The University of Calgary</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Aho, Morgan" sort="Aho, Morgan" uniqKey="Aho M" first="Morgan" last="Aho">Morgan Aho</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0418553</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0418553 INIST</idno>
<idno type="RBID">Pascal:05-0418553</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000890</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000433</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation</title>
<author><name sortKey="Hagen, Brad" sort="Hagen, Brad" uniqKey="Hagen B" first="Brad" last="Hagen">Brad Hagen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Esther, Chris Armstrong" sort="Esther, Chris Armstrong" uniqKey="Esther C" first="Chris Armstrong" last="Esther">Chris Armstrong Esther</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Ikuto, Roland" sort="Ikuto, Roland" uniqKey="Ikuto R" first="Roland" last="Ikuto">Roland Ikuto</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Senior's Health, The Chinook Health Region</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Williams, Robert J" sort="Williams, Robert J" uniqKey="Williams R" first="Robert J." last="Williams">Robert J. Williams</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Le Navenec, Carole Lynne" sort="Le Navenec, Carole Lynne" uniqKey="Le Navenec C" first="Carole-Lynne" last="Le Navenec">Carole-Lynne Le Navenec</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Nursing, The University of Calgary</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Aho, Morgan" sort="Aho, Morgan" uniqKey="Aho M" first="Morgan" last="Aho">Morgan Aho</name>
</author>
</analytic>
<series><title level="j" type="main">International psychogeriatrics</title>
<title level="j" type="abbreviated">Int. psychogeriatr.</title>
<idno type="ISSN">1041-6102</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International psychogeriatrics</title>
<title level="j" type="abbreviated">Int. psychogeriatr.</title>
<idno type="ISSN">1041-6102</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada</term>
<term>Chemotherapy</term>
<term>Elderly</term>
<term>Epidemiology</term>
<term>Homes for the aged</term>
<term>Long term</term>
<term>Neuroleptic</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Psychotropic</term>
<term>Public health</term>
<term>Review</term>
<term>Senile dementia</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Neuroleptique</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Psychotrope</term>
<term>Canada</term>
<term>Long terme</term>
<term>Epidémiologie</term>
<term>Prévalence</term>
<term>Santé publique</term>
<term>Démence sénile</term>
<term>Etablissement troisième âge</term>
<term>Article synthèse</term>
<term>Parkinson maladie</term>
<term>Personne âgée</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Santé publique</term>
<term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background and aims: Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation. Method: A comparative descriptive design was used. Pharmacy and chart data on antipsychotic use were gathered for three separate one-month periods during one year. Data were collected both in a facility experiencing relocation of all residents to a new facility, and in a facility not undergoing relocation. The three one-month data collection periods covered a one-month period before the relocation, immediately after the relocation, and six months after the relocation. Results: In the facility not experiencing relocation, an average of 31.3% of all residents were receiving antipsychotics. Residents in this facility received antipsychotics for an average length of 0.81 years, and 20.8% of all antipsychotic prescriptions reflected dose reductions within six months of the start of the prescription. Only 8.1% of prescriptions had accompanying documentation on the behavioral indication for the use of antipsychotics. A total of 73.4% of all antipsychotics were 'atypical' antipsychotics, and 13.5% of all antipsychotic prescriptions were written as 'p.r.n.' (as needed). While the use of antipsychotics remained relatively constant in the non-relocation facility (between 30.3% and 33.1% of all residents), the percentage of residents receiving antipsychotics in the facility experiencing a relocation climbed significantly; from 21.5% six months before the move, to 32.6% immediately after the move, to 36.9% six months after the move. Conclusion: These findings, when compared with the U.S. standards on antipsychotic use (OBRA), suggest the need for additional research on antipsychotic use in Canadian LTC facilities.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1041-6102</s0>
</fA01>
<fA03 i2="1"><s0>Int. psychogeriatr.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HAGEN (Brad)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ESTHER (Chris Armstrong)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>IKUTO (Roland)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WILLIAMS (Robert J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LE NAVENEC (Carole-Lynne)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>AHO (Morgan)</s1>
</fA11>
<fA14 i1="01"><s1>School of Health Sciences, The University of Lethbridge</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Senior's Health, The Chinook Health Region</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>School of Nursing, The University of Calgary</s1>
<s2>Alberta</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>179-193</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26959</s2>
<s5>354000131507690030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0418553</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>International psychogeriatrics</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background and aims: Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation. Method: A comparative descriptive design was used. Pharmacy and chart data on antipsychotic use were gathered for three separate one-month periods during one year. Data were collected both in a facility experiencing relocation of all residents to a new facility, and in a facility not undergoing relocation. The three one-month data collection periods covered a one-month period before the relocation, immediately after the relocation, and six months after the relocation. Results: In the facility not experiencing relocation, an average of 31.3% of all residents were receiving antipsychotics. Residents in this facility received antipsychotics for an average length of 0.81 years, and 20.8% of all antipsychotic prescriptions reflected dose reductions within six months of the start of the prescription. Only 8.1% of prescriptions had accompanying documentation on the behavioral indication for the use of antipsychotics. A total of 73.4% of all antipsychotics were 'atypical' antipsychotics, and 13.5% of all antipsychotic prescriptions were written as 'p.r.n.' (as needed). While the use of antipsychotics remained relatively constant in the non-relocation facility (between 30.3% and 33.1% of all residents), the percentage of residents receiving antipsychotics in the facility experiencing a relocation climbed significantly; from 21.5% six months before the move, to 32.6% immediately after the move, to 36.9% six months after the move. Conclusion: These findings, when compared with the U.S. standards on antipsychotic use (OBRA), suggest the need for additional research on antipsychotic use in Canadian LTC facilities.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B03</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B18C05A</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="04" i2="X"><s0>002B18C13</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Canada</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Canada</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Canadá</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Long terme</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Long term</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Public health</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Démence sénile</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Senile dementia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Demencia senil</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Etablissement troisième âge</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Homes for the aged</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Establecimiento tercera edad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Review</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Elderly</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Anciano</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fN21><s1>290</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000433 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000433 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0418553
   |texte=   Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation

Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri